Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight

Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.

10/13/2026, 1:00 PM • GlobeNewswire

Why Harmony Biosciences Stock Got Mashed on Monday

Harmony Biosciences stock fell over 5% on Monday following the announcement of a planned CEO succession. Current COO Peter Anastasiou will replace CEO Jeffrey Dayno effective January 1, 2027, in a planned transition. Despite the company maintaining its strategic priorities and reiterating full-year Wakix revenue guidance of $1-$1.04 billion, investors reacted negatively to the leadership change. The analyst suggests this may present a buying opportunity at a discount.

10/12/2026, 7:16 PM • The Motley Fool

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth

Harmony Biosciences announced that Peter Anastasiou, current Sr. EVP and COO, will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno who will retire after nine years. The company reiterates its full-year 2026 WAKIX net revenue guidance of $1.0-1.04 billion and remains on track to report BP-205 MAD study data in Q4 2026.

10/12/2026, 7:00 AM • GlobeNewswire

A beaten-down biotech just lost a meaningful backer — should you care?

Bridge City Capital fully exited its position in Harmony Biosciences Holdings, selling all 237,103 shares worth approximately $7.77 million during Q1 2026. The stake, which represented 2.6% of the fund's AUM in the prior quarter, was completely liquidated. Harmony Biosciences, a rare neurological disorder treatment developer, has underperformed the S&P 500 by 42.07 percentage points over the past year.

05/19/2026, 5:33 PM • The Motley Fool

12 Small-Cap Stocks Primed for Breakouts as Earnings Approach

The Russell 2000 small-cap index has outperformed major indices, rising 8.40% in the past month. With Q1 2026 earnings season underway, analysts expect small-cap earnings growth of 18.4% compared to 9.8% for S&P 500 companies. The article highlights three undervalued small-cap stocks with significant upside potential: Goosehead Insurance (technology-driven insurance broker), EverCommerce (SaaS platform for service businesses), and Harmony Biosciences (rare disease biopharmaceutical company).

04/16/2026, 1:21 PM • Investing

12 Small-Cap Stocks Primed for Breakouts as Earnings Approach

The Russell 2000 small-cap index has outperformed major indices, rising 8.40% in the past month. With Q1 2026 earnings season underway, small-cap companies are expected to deliver 18.4% earnings growth compared to 9.8% for S&P 500 companies. The article highlights three undervalued small-cap stocks with significant upside potential: Goosehead Insurance (GSHD), EverCommerce (EVCM), and Harmony Biosciences (HRMY), benefiting from digital transformation trends and favorable market conditions.

04/16/2026, 12:39 PM • Investing

Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800

Harmony Biosciences' CFO Sandip Kapadia sold all 20,961 of her directly held shares for approximately $752,800 on January 15, 2026, fully exiting her equity position. The sale was part of a pre-planned Rule 10b5-1 trading plan. Despite the insider exit, the company reported strong Q3 2025 earnings and expects to generate over $1 billion in revenue from its flagship product WAKIX by end of 2026.

01/31/2026, 10:19 PM • The Motley Fool

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

Harmony Biosciences has achieved remarkable financial success with its narcolepsy drug Wakix, growing sales at 40% CAGR to nearly $870 million and achieving profitability with $186 million in net income. However, the stock has remained flat since its IPO due to concerns including a 2023 short-seller report alleging fraud, pending patent expiration in 2030, and intense competition from Jazz Pharmaceuticals' blockbuster treatments Xywav and Xyrem.

01/27/2026, 12:02 PM • The Motley Fool